ROME Therapeutics vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
ROME Therapeutics pioneers drugs targeting the dark genome — genomic repeats implicated in cancer and autoimmune disease; raised ~$200M backed by J&J, BMS, and Sanofi; advancing lead LINE-1 inhibitor toward human trials.
About
ROME Therapeutics is a Cambridge, Massachusetts-based biopharmaceutical company pioneering a novel approach to drug discovery by targeting the "dark genome" — the vast portion of the human genome composed of repetitive DNA sequences that has historically been ignored or considered non-functional. ROME''s scientific hypothesis is that specific classes of genomic repeats, particularly LINE-1 (Long Interspersed Nuclear Elements) retrotransposons, become aberrantly activated in diseased cells — including cancer cells and cells involved in autoimmune disorders — and drive disease pathology through mechanisms distinct from traditional drug targets.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.